Global CAR T therapy trial shows high rates of durable remission for NHL - Medical Xpress

Medical Xpress

Global CAR T therapy trial shows high rates of durable remission for NHL Medical Xpress In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. Results from a ... CAR T-Cell Therapies Drive Outcomes in Lymphoma, MyelomaPR Newswire (press release) Phase 2 CAR-T study reports significant remission rates at 15-month follow upEurekAlert (press release) Gilead's new drug keeps 56 percent of lymphoma trial patients aliveReuters Markets Insider -Motley Fool -Financial Times all 10 news articles »

from Health - Google News http://ift.tt/2Aa0BWU